Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 in refractory focal onset epilepsy
2023-508539-30-00Phase 2Suspended
- Sponsor
- Biohaven Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in Focal Onset Epilepsy comparing BHV-7000 plus background anti-seizure medications with Placebo plus background anti-seizure medications (2 arms). Primary endpoints: Safety and 50% responder rate. Started Oct 2024; status: suspended.
02
Drugs
opakalim
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2023-508539-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508539-30-00.